Adicet Bio
ACET
53 hedge funds and large institutions have $36.2M invested in Adicet Bio in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 20 closing their positions.
300% more call options, than puts
Call options by funds: $12K | Put options by funds: $3K
166% more capital invested
Capital invested by funds: $13.6M → $36.2M (+$22.6M)
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
4% more funds holding
Funds holding: 51 → 53 (+2)
0.09% more ownership
Funds ownership: 0.32% → 0.41% (+0.09%)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.1M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.55M |
| 3 |
AG
Artal Group
Luxembourg
|
+$1.67M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$680K |
| 5 |
D.E. Shaw & Co
New York
|
+$316K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.45M |
| 2 |
BlackRock
New York
|
-$1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$364K |
| 4 |
RL
Ruffer LLP
London,
United Kingdom
|
-$313K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$272K |
ACET Hedge Fund Activity: Q2 2020 in Review
53 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2020, worth a combined $36.2M — up 166% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ACET positions and 20 closed out — a net gain of 2 holders — while 8 added to existing stakes and 16 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $5.1M. The largest seller was Morgan Stanley, cutting an estimated $1.45M.
- 53 institutional investors held Adicet Bio (ACET) as of Q2 2020, up from 51 in Q1 2020.
- Funds reported $36.2M of Adicet Bio stock for Q2 2020, up 166% quarter-over-quarter.
- 22 funds opened new Adicet Bio positions in Q2 2020 and 20 closed out, a net change of +2 holders.
- The largest Adicet Bio buyer in Q2 2020 was Nantahala Capital Management, an estimated $5.1M added.
- The largest Adicet Bio seller in Q2 2020 was Morgan Stanley, an estimated $1.45M sold.
Based on aggregated 13F filings for Q2 2020.